DCF 987

Drug Profile

DCF 987

Alternative Names: Dextran-1; Usherdex; Usherdex-4

Latest Information Update: 15 Dec 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polydex Pharmaceuticals
  • Developer BCY LifeSciences
  • Class Antibacterials; Expectorants; Glucans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 09 Oct 2007 ALIGN Pharmaceuticals has been acquired by Cyclacel Pharmaceuticals
  • 18 May 2007 BCY LifeSciences terminates its licence for DCF 987
  • 25 Feb 2005 DCF 987 has been licensed to ALIGN Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top